Photocure Inc. et al., 2026-06-03: US label for hexaminolevulinate (Cysview), approved only for cystoscopic DETECTION of bladder cancer including carcinoma in situ – it is a diagnostic imaging agent, not an approved photodynamic treatment.
CYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) based on a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer
Section 1 (Indications and Usage)
Photocure Inc. et al., 2026-06-03: US label for hexaminolevulinate (Cysview), approved only for cystoscopic DETECTION of bladder cancer including carcinoma in situ – it is a diagnostic imaging agent, not an approved photodynamic treatment. C8 label record – bladder. Country: USA. Approved agent: hexaminolevulinate HCl, intravesical, blue light cystoscopy. Not methylene blue, and not a therapy. Relevant because 'PDT for bladder cancer' in the popular literature often conflates this diagnostic use with treatment. Study type: regulatory record.
